

SOME PATENT APPLICATIONS IN VECTORS AND EXPRESSION SYSTEMS

Patent #	Subject	Assignee	Author	Status*
WO 9627678	Yeast vector expressing cytochrome P450 and NADPH-dependent reductase. Useful for hydroxylation of long-chain alkane(s) and fatty acids.	Max-Delbrück Cent Molekulare Medizin Berlin	Kaergel E, Kaminski K, Mauersberger S, Scheller U, Schunck W, Zimmer T	9/12/96 A1
WO 9627676	Vector for stable transfection of cells, produces peptide(s) in high yield. Contains translation inhibition factor gene controlled by weak eukaryotic promoter and internal ribosome entry site.	Expression Systems San Francisco, CA QBI Enterprises Ltd Omer, Israel	Grossman Z, Nopnar Y, Zurr D	9/12/96 A2
WO 9627672	New modified herpes simplex type 1 viruses including a non-herpes gene. Especially useful for gene therapy of neurological disorders such as amyotrophic lateral sclerosis.	Fink DJ, Glorioso JC	Fink DJ, Glorioso JC	9/12/96 A1
WO 9626745	Gene delivery system, including liposome or dendrimer and perpetuation molecule—especially for gene therapy, provides efficient and stable expression of chimeric genes more safely than use of viruses.	Creighton Univ Omaha, NE	Hodgson CP	9/6/96 A1
WO 9626744	New human natural killer lytic-associated protein. Useful for treating cancer, viral infections, graft vs. host or autoimmune diseases.	Univ Arkansas Fayetteville, AR	Kornbluth J	9/6/96 A1
WO 9608510	Human hematopoietin receptor Hu-B1219. Useful in design of molecular probes for prenatal testing and cancer diagnosis.	Progenitor Inc Columus, OH	Cioffi J, Shafer AW, Snodgrass RH, Zupancic TJ	3/21/96 A1
WO 9519435 WO 9519435	Production of recombinant T-cell antigen receptor V region proteins for use in the diagnosis, treatment, prevention or suppression of immune-related diseases or disorders, especially multiple sclerosis.	T Cell Sciences Inc Needham, MA	Kung PC, Makrides SC	7/20/95 A2 8/24/95 A3
WO 9514778	New bone morphogenetic protein receptor kinase protein. Used for identifying compounds capable of binding it and for developing therapeutic compounds and detection system(s).	Procter & Gamble Cincinnati, OH	Cook JS, Correa PE, Koenig BB, Rosenbaum JS, Ting J	6/1/95 A2
WO 9514091 WO 9514091	New viral vector expressing activator or precursor of cytotoxic compound. Under control of an event or tissue-specific promoter. Used to treat tumors and viral or other infections.	Viagene Inc San Diego, CA Chiron Viagene Inc	Barber JR, Gruber HE, Jolly DJ	5/26/95 A2 10/26/95 A3
WO 9500651	Nucleotide sequences encoding stratum corneum chymotryptic enzyme and related vectors, transformed cells and polypeptides. Useful for treating skin disorders, e.g., acne or psoriasis.	Symbicom AB Urmea, Sweden	Egelrud T, Hansson L	1/5/95 A1
WO 9508624	Human phospholipase C- α and DNA encoding it. Useful as an antiinflammatory.	Hirano N, Shionogi & Co Ltd, Osaka	Hirai H, Hirano N	3/30/95 A1
WO 9208736	New hirudin mutant HV1C3 with antithrombin activity. Useful as anticoagulant without preventing external wounds from healing.	Nippon Mining Co Japan Energy Corp Tokyo	Furuya H, Inoue Y, Matsuda H, Misawa S	5/29/92 A1
WO 9116430	New recombinant polypeptide comprising a T-cell protein. Used to regulate T-cell development and tumorigenic phenotype and to block T-cell activation in autoimmune disease.	Research Development Foundation Arlington, VA	Macleod CL	10/31/91 A
WO 9007341	Purified sciatic nerve ciliary neurotrophic factor and recombinant CNTF. Useful for reducing damage to nervous system caused by disease or injury.	Synergen Inc Amgen Boulder Inc Boulder, CO	Collins FD, Ko C, Lin L, Mismar D	7/12/90 A
WO 8904669	Purified hepatitis C virus and associated nucleic acids and polypeptide(s).	Chiron Corp Emeryville, CA	George K, Michel H, Zhou Q, Choo QL, Houghton M, Kuo G, Choo Q	6/1/90 A
WO 8603517	New DNA sequence coding for new hirudin like polypeptide. Useful as thrombin antagonist, e.g., for inhibiting blood coagulation.	Gen-Bio-Tec Ges, Plantorgan Werk Christensen KG, Ciba Geigy AG, UCP Gen-Pharma AG	Fortkamp E, Rieger M, Sommer R, Fink E	6/19/86 A

Source: Derwent Information, McLean, VA. *(WO) A, Open for public inspection application (OPIA); A1, OPIA with international search report (from 9220); A2, OPIA without international search report (from 9220); A3, OPIA's search report for A2 (from 9220). For further details contact Derwent scientific and patent information at Derwent North America, 1420 Spring Hill Road, Suite 525, McLean, VA 22102. Tel: 1 (800) DERWENT (info@derwent.com).